| Source | M.W. | 421.3 | CAS No. | 879085-55-9 | |
|---|---|---|---|---|---|
| Structural Info | C19H14Cl2N2O3S |
||||
| Formulation | Powder | ||||
| Reconstitution | Before reconstitution, we recommend a brief spin to drive down any material dislodged from the bottom of the tube. The compound is soluble in DMSO. | ||||
| Stability | The powder is stable for at least 2 year if stored at -20 °C. The dissolved compound is stable for at least 1 month at 4 °C, but should be stored in aliquots at -20 °C for longer term. Protect from light. |
||||
| Purity | Greater than 99% as determined by LC/MS analysis. LC/MS and/or NMR data available upon request. | ||||
| Biological Activity | In a cell-based assay measuring the activation of the Gli-1 reporter gene, this compound gives IC50 of 5-20 nM. | ||||
| Country of Origin | USA | ||||
GDC-0449 (Vismodegib) is potent antagonist of SMO (smoothened). This small molecule compound is a hedgehog pathway inhibitor by directly binding to SMO. This molecule has been developed by Genentech for clinical application against hedgehog-dependent cancers.
Ref: Robarge KD, et al. Bioorg Med Chem Lett. Oct 1 2009 19: 5576-81;
van Hoff DD, et al. N Engl J Med. Sep 17, 2009 361: 1164-72;
Rudin CM et al. N Engl J Med. 2009 Sep 17; 361(12):1173-8.
Okabe S, Tauchi T, Tanaka Y, et al., Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on
BCR-ABL-positive leukemia cells. Stem Cells Dev. 2012 Nov 1;21(16):2939-48.
http://www.ncbi.nlm.nih.gov/pubmed/22642671
BCR-ABL-positive leukemia cells. Stem Cells Dev. 2012 Nov 1;21(16):2939-48.
http://www.ncbi.nlm.nih.gov/pubmed/22642671